The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TXMD | +7.04% | -97.71% | -53.03% | -97% |
| S&P | +12.93% | +85.68% | +13.18% | +444% |
TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.
Pharmaceutical stocks are popular with Robinhood Investors, including three I would stay away from and one that I wouldn't.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.78M | 43.3% |
| Gross Profit | $0.69M | 52.5% |
| Gross Margin | 87.76% | 5.3% |
| Market Cap | $12.44M | -35.0% |
| Market Cap / Employee | $12.44M | 0.0% |
| Employees | 1 | 0.0% |
| Net Income | $0.05M | 108.8% |
| EBITDA | -$0.73M | 3.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.12M | 41.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.41M | -6.3% |
| Short Term Debt | $1.07M | -33.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.19% | 9.0% |
| Return On Invested Capital | -16.65% | 15.1% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $1.05M | 665.4% |
| Operating Free Cash Flow | $1.05M | 665.4% |
| Metric | Q3 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 41.19 | - | |||
| Price to Book | 0.37 | 0.39 | 0.50 | 0.46 | -34.10% |
| Price to Sales | 5.63 | 5.80 | 5.25 | 4.45 | -62.90% |
| Price to Tangible Book Value | 0.44 | 0.46 | 0.59 | 0.54 | -35.29% |
| Price to Free Cash Flow TTM | 13.55 | 7.59 | 16.04 | 6.02 | - |
| Enterprise Value to EBITDA | -56.76 | -17.31 | -23.31 | -16.09 | -42.89% |
| Free Cash Flow Yield | 7.4% | 13.2% | 6.2% | 16.6% | - |
| Return on Equity | -8.2% | -7.7% | -2.0% | 0.3% | -101.86% |
| Total Debt | $7.18M | $6.97M | $6.60M | $6.48M | -12.39% |
No podcast episodes available.
TXMD earnings call for the period ending June 30, 2022.
TXMD earnings call for the period ending March 31, 2022.
TXMD earnings call for the period ending December 31, 2021.
TXMD earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
